Fri, 30th Apr 2021 07:10
April 30 (Reuters) - AstraZeneca said on Friday it
expected higher sales in the second half of the year, as it
reported first-quarter profit and sales ahead of analysts'
average expectations, including $275 million in COVID-19 vaccine
sales.
(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger
in Frankfurt; editing by John Stonestreet)
(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the Europ...
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommend...
June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worse...
June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by abo...
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:
Astrazeneca (AZN)